Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorPOIREL, Laurent
dc.contributor.authorORTIZ DE LA ROSA, José-Manuel
dc.contributor.authorKIEFFER, Nicolas
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorDUBOIS, Veronique
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorJAYOL, Aurelie
dc.contributor.authorNORDMANN, Patrice
dc.date.accessioned2023-12-01T10:50:03Z
dc.date.available2023-12-01T10:50:03Z
dc.date.issued2019-01-01
dc.identifier.issn1098-6596en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/186300
dc.description.abstractEnA clinical isolate resistant to all β-lactams, including ceftolozane-tazobactam and carbapenems, was recovered. It belonged to sequence type 235 and produced the extended-spectrum β-lactamase (ESBL) GES-6 differing from GES-1 by two amino acid substitutions (E104K and G170S). GES-6 possessed an increased hydrolytic activity toward carbapenems and to ceftolozane and a decreased susceptibility to β-lactamase inhibitors compared to GES-1, except for avibactam. We show here that resistance to ceftolozane-tazobactam may occur through acquisition of a specific ESBL in but that ceftazidime-avibactam combination remains an effective alternative.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enAmino Acid Substitution
dc.subject.enAnti-Bacterial Agents
dc.subject.enAzabicyclo Compounds
dc.subject.enCarbapenems
dc.subject.enCeftazidime
dc.subject.enCephalosporins
dc.subject.enDrug Combinations
dc.subject.enGene Expression
dc.subject.enHumans
dc.subject.enMicrobial Sensitivity Tests
dc.subject.enPseudomonas Infections
dc.subject.enPseudomonas aeruginosa
dc.subject.enTazobactam
dc.subject.enbeta-Lactam Resistance
dc.subject.enbeta-Lactamases
dc.title.enAcquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in Pseudomonas aeruginosa
dc.title.alternativeAntimicrob Agents Chemotheren_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1128/AAC.01809-18en_US
dc.subject.halSciences du Vivant [q-bio]/Microbiologie et Parasitologieen_US
dc.identifier.pubmed30323045en_US
bordeaux.journalAntimicrobial Agents and Chemotherapyen_US
bordeaux.volume63en_US
bordeaux.hal.laboratoriesMFP (Laboratoire Microbiologie Fondamentale et Pathogénicité) - UMR 5234en_US
bordeaux.issue1en_US
bordeaux.institutionCNRSen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.identifierhal-04317650
hal.version1
hal.date.transferred2023-12-01T10:50:05Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Antimicrobial%20Agents%20and%20Chemotherapy&rft.date=2019-01-01&rft.volume=63&rft.issue=1&rft.eissn=1098-6596&rft.issn=1098-6596&rft.au=POIREL,%20Laurent&ORTIZ%20DE%20LA%20ROSA,%20Jos%C3%A9-Manuel&KIEFFER,%20Nicolas&DUBOIS,%20Veronique&JAYOL,%20Aurelie&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée